GR
Grifols SA
GRF.MC·BMEBarcelona ESFounded 194023,000 employees
Mid CapbiotechPublicHematology
Platform: Plasma Fractionation
Market Cap
$6B
All Drugs
4
Clinical Trials
6
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (GRF.MC)
Loading GRF.MC stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| GRF-1969 | GRF-1969 | Phase 1/2 | 2 | KIF18A | T2D | ||
| GRF-2905 | GRF-2905 | Phase 1 | 2 | Menin | EoEMCL | ||
| GRF-8988 | GRF-8988 | Phase 2/3 | 1 | CD20 | Heart Failure | ||
| Sovafutibatinib | GRF-7095 | Phase 1/2 | 1 | SHP2 | SCDALS |
SEC Filings & Financial Documents
SEC filings are not available for BME-listed companies.
Grifols SA trades on BME (ES). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (6)